Subtype
Malignant Neck Neoplasm
CI-CAN-00001148Explore in graph →
607 active trials11 approved drugs67 evidence items
- NCIt
- C4940
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001148Explore in graph →
Clinical trials
2,145 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (181)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04541355 | Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin | completed | Phase 2 | 16 | Hyunseok Kang, MDOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT06455410 | GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma | recruiting | Phase 2 | 216 | Sun Yat-sen UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05513573 |
| active not recruiting |
| Phase 2 |
| 75 |
| Shanghai Henlius BiotechINDUSTRY |
| 1 |
| Jun 17, 2024 |
| clinicaltrials |
| NCT04782856 | Energy Metabolism in Thyroidectomized Patients | completed | Phase 2 | 13 | Virginia Commonwealth UniversityOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT04161391 | Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations | terminated | Phase 1 / Phase 2 | 41 | Turning Point Therapeutics, Inc.INDUSTRY | 2 | Jun 13, 2024 | clinicaltrials |
| NCT05955105 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 200 | Innolake BiopharmINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT04444869 | Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer(ENID) | unknown | Phase 2 | 28 | University of Missouri-ColumbiaOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT06019130 | Nivolumab in Children and Adults With Nasopharyngeal Carcinoma(NPC-Nivo) | recruiting | Phase 2 | 57 | German Society for Pediatric Oncology and Hematology GPOH gGmbHOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT04396886 | Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC | completed | Phase 2 | 38 | The University of Hong KongOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT03025958 | Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | completed | Phase 2 | 30 | Zhejiang Cancer HospitalOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT06151743 | Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma | recruiting | Phase 2 | 32 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT04742959 | Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 203 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT03565536 | Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer | completed | Phase 2 | 18 | Fujian Medical UniversityOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT03601507 | Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer | terminated | Phase 2 | 9 | University of ArizonaOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06364826 | Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma | unknown | Phase 2 | 60 | Zhejiang Cancer HospitalOTHER | 0 | Apr 15, 2024 | clinicaltrials |
| NCT06362694 | Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy | unknown | Phase 2 | 10 | Saint Petersburg State University, RussiaOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT04830267 | The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC | unknown | Phase 2 | 39 | Chongqing University Cancer HospitalOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT05098119 | Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002) | recruiting | Phase 2 | 43 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT06331845 | Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 39 | Fujian Cancer HospitalOTHER_GOV | 0 | Mar 26, 2024 | clinicaltrials |
| NCT04731740 | Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer | withdrawn | Phase 2 | 0 | Saint Petersburg State University, RussiaOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT04739566 | Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer(ANAPLAST-NEO) | withdrawn | Phase 2 | 0 | Saint Petersburg State University, RussiaOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT03558191 | SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy. | completed | Phase 2 | 156 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06259721 | Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 22 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT05011227 | Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma | unknown | Phase 2 | 100 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT05860335 | Efficacy and Safety of Toripalimab Combined With AP-induced Chemotherapy Followed in Non-metastatic IVB Hypopharyngeal Cancer | unknown | Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT00390325 | Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Feb 6, 2024 | clinicaltrials |
| NCT05385926 | Combining RT With Immunotherapy and Chemotherapy in Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 34 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT06241599 | A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) | recruiting | Phase 2 / Phase 3 | 300 | Sun Yat-sen UniversityOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT05675605 | A Study of TY-1091 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 248 | TYK Medicines, IncINDUSTRY | 1 | Jan 30, 2024 | clinicaltrials |
| NCT03708822 | Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 48 | Sun Yat-sen UniversityOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT04327999 | Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System | terminated | Phase 2 | 9 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT04398524 | A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC | unknown | Phase 2 | 65 | ISA PharmaceuticalsINDUSTRY | 9 | Jan 16, 2024 | clinicaltrials |
| NCT02244463 | A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer | completed | Phase 1 / Phase 2 | 46 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT03669718 | A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC | unknown | Phase 2 | 194 | ISA PharmaceuticalsINDUSTRY | 13 | Dec 29, 2023 | clinicaltrials |
| NCT06121271 | Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications | not yet recruiting | Phase 2 | 110 | University College, LondonOTHER | 0 | Dec 7, 2023 | clinicaltrials |
| NCT06156878 | PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy | unknown | Phase 2 | 41 | Fudan UniversityOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT06156891 | PD-1 Inhibitor Based Induction Chemotherapy Followed by De-escalation Protocols in OPSCC | unknown | Phase 2 | 60 | Fudan UniversityOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT06146985 | Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer | unknown | Phase 2 | 67 | Ruijin HospitalOTHER | 0 | Nov 28, 2023 | clinicaltrials |
| NCT05576272 | A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma | unknown | Phase 2 / Phase 3 | 460 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 22, 2023 | clinicaltrials |
| NCT03618134 | Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner | terminated | Phase 1 / Phase 2 | 19 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT05182931 | A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)(I-FIRST) | unknown | Phase 2 | 80 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT03906058 | Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy | completed | Phase 2 | 39 | Sun Yat-sen UniversityOTHER | 1 | Oct 25, 2023 | clinicaltrials |
| NCT04277858 | Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Oropharyngeal Cancer.(NECTORS) | unknown | Phase 2 | 60 | Nader SadeghiOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06087068 | Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma | recruiting | Phase 2 | 140 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT06079333 | NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)(NEO-ATACT) | recruiting | Phase 2 | 20 | Leiden University Medical CenterOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT05626829 | Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma | unknown | Phase 2 | 18 | Jian GuanOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06055816 | Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma | recruiting | Phase 2 | 40 | Zhejiang Cancer HospitalOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT06051747 | Patient-Customized Bioprinting Technology for Practical Regeneration of the Respiratory Tract (Trachea) | unknown | Phase 1 / Phase 2 | 1 | Ja Seong Bae, MD, phDOTHER | 1 | Sep 25, 2023 | clinicaltrials |
| NCT05520814 | PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial | unknown | Phase 2 | 50 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06039631 | Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer | recruiting | Phase 2 | 82 | Fudan UniversityOTHER | 1 | Sep 15, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jun 28, 2024source: clinicaltrials